Molecular characteristics of hepatocellular carcinomas from different age groups
Metrics: PDF 689 views | HTML 996 views | ?
Celina Ang1, Anthony Shields2, Joanne Xiu3, Zoran Gatalica4, Sandeep Reddy3, Mohamed E. Salem5, Carol Farhangfar6, Jimmy Hwang7, Igor Astsaturov3,7 and John L. Marshall5
1Department of Medicine, Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2Department of Oncology, Molecular Imaging & Diagnostics Program, Karmanos Cancer Center, Wayne State University, Detroit, MI, USA
3Department of Medical Affairs, Caris Life Sciences, Phoenix, AZ, USA
4Department of Pathology, Caris Life Sciences, Phoenix, AZ, USA
5Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown, University, Washington, DC, USA
6Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA
7Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Celina Ang, email: firstname.lastname@example.org
Keywords: hepatocellular carcinoma; age differences; multiplatform profiling; pathogenic mutations
Received: July 03, 2017 Accepted: August 31, 2017 Published: September 27, 2017
While most patients in Western countries who are diagnosed with HCC are in their 50s and 60s, HCCs diagnosed at extremes of the age spectrum (i.e., < 40 years and ≥ 75 years) are less common and have been linked with distinct geographic locations and etiologies. Using multiplatform profiling, we identified differences in genetic alterations and protein expression in different age groups within a large cohort of HCC patients (N = 421). Young adult HCC patients (18-39 years’ old) were more likely to be female, living in the West and Midwestern United States, and showed decreased androgen receptor, drug resistance and pro-angiogenic protein expression compared to older patients. TP53 mutations were the most frequent alteration in young adults (19%), whereas CTNNB1 mutations occurred in 30-33% of patients ≥ 40 years’ old. The overall frequency of pathogenic and presumed pathogenic mutations was observed to increase significantly with advancing age. To our knowledge, these data represent one of the only studies to analyze age-specific molecular profiles in HCC, and provide a basis for further exploration and validation of these findings with respect to their clinical and therapeutic implications.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.